Application value of CT radiomic nomogram in predicting T790M mutation of lung adenocarcinoma

被引:3
|
作者
Li, Xiumei [1 ]
Chen, Jianwei [2 ]
Zhang, Chengxiu [3 ]
Han, Zewen [1 ]
Zheng, Xiuying [1 ]
Cao, Dairong [1 ,4 ,5 ,6 ]
机构
[1] Fujian Med Univ, Affiliated Hosp 1, Dept Anesthesiol, Fuzhou 350005, Fujian, Peoples R China
[2] Fujian Prov Canc Hosp, Dept Pathol, Fuzhou 350014, Fujian, Peoples R China
[3] East China Normal Univ, Sch Phys & Elect Sci, Shanghai Key Lab Magnet Resonance, Shanghai 200062, Peoples R China
[4] Fujian Med Univ, Affiliated Hosp 1, Natl Reg Med Ctr, Dept Radiol, Binhai Campus, Fuzhou 350212, Fujian, Peoples R China
[5] Fujian Med Univ, Affiliated Hosp 1, Fujian Key Lab Precis Med Canc, Fuzhou 350005, Fujian, Peoples R China
[6] Fujian Med Univ, Affiliated Hosp 1, Key Lab Radiat Biol, Fujian Higher Educ Inst, Fuzhou 200062, Peoples R China
关键词
Lung adenocarcinoma; Radiomics; Computed tomography; T790M; CANCER;
D O I
10.1186/s12890-023-02609-y
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
BackgroundThe purpose of this study was to develop a radiomic nomogram to predict T790M mutation of lung adenocarcinoma base on non-enhanced CT lung images.MethodsThis retrospective study reviewed demographic data and lung CT images of 215 lung adenocarcinoma patients with T790M gene test results. 215 patients (including 52 positive) were divided into a training set (n = 150, 36 positive) and an independent test set (n = 65, 16 positive). Multivariate logistic regression was used to select demographic data and CT semantic features to build clinical model. We extracted quantitative features from the volume of interest (VOI) of the lesion, and developed the radiomic model with different feature selection algorithms and classifiers. The models were trained by a 5-fold cross validation strategy on the training set and assessed on the test set. ROC was used to estimate the performance of the clinical model, radiomic model, and merged nomogram.ResultsThree demographic features (gender, smoking, emphysema) and ten radiomic features (Kruskal-Wallis as selection algorithm, LASSO Logistic Regression as classifier) were determined to build the models. The AUC of the clinical model, radiomic model, and nomogram in the test set were 0.742(95%CI, 0.619-0.843), 0.810(95%CI, 0.696-0.907), 0.841(95%CI, 0.743-0.938), respectively. The predictive efficacy of the nomogram was better than the clinical model (p = 0.042). The nomogram predicted T790M mutation with cutoff value was 0.69 and the score was above 130.ConclusionThe nomogram developed in this study is a non-invasive, convenient, and economical method for predicting T790M mutation of lung adenocarcinoma, which has a good prospect for clinical application.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Sequential small cell transformation and T790M mutation in an epidermal growth factor-mutant lung adenocarcinoma: A rare occurrence with significant management implications
    Shastri, Malvika
    Gupta, Parikshaa
    Gupta, Nalini
    Singh, Navneet
    Bal, Amanjit
    Srinivasan, Radhika
    Khosla, Divya
    CYTOPATHOLOGY, 2022, 33 (06) : 732 - 737
  • [32] CT-based radiomics nomogram for predicting visceral pleural invasion in peripheral T1-sized solid lung adenocarcinoma
    Cai, Xiaoting
    Wang, Ping
    Zhou, Huihui
    Guo, Hao
    Yang, Xinyu
    Dai, Zhengjun
    Ma, Heng
    AMERICAN JOURNAL OF CANCER RESEARCH, 2023, 13 (12):
  • [33] Nomogram based on preoperative CT imaging predicts the EGFR mutation status in lung adenocarcinoma
    Zhang, Guojin
    Zhang, Jing
    Cao, Yuntai
    Zhao, Zhiyong
    Li, Shenglin
    Deng, Liangna
    Zhou, Junlin
    TRANSLATIONAL ONCOLOGY, 2021, 14 (01):
  • [34] Predicting the T790M mutation in non-small cell lung cancer (NSCLC) using brain metastasis MR radiomics: a study with an imbalanced dataset
    Wu, Wen-Feng
    Lai, Kuan-Ming
    Chen, Chia-Hung
    Wang, Bai-Chuan
    Chen, Yi-Jen
    Shen, Chia-Wei
    Chen, Kai-Yan
    Lin, Eugene C.
    Chen, Chien-Chin
    DISCOVER ONCOLOGY, 2024, 15 (01)
  • [35] The clinicopathological features and possible physiological mechanisms of only the EGFR-T790M primary mutation in patients with lung adenocarcinoma
    Zhao, Ping
    Xu, Liming
    Zhu, Huijuan
    Ding, Wei
    Tang, Hui
    PATHOLOGY RESEARCH AND PRACTICE, 2024, 259
  • [36] Development and validation of a radiomic nomogram based on pretherapy dual-energy CT for distinguishing adenocarcinoma from squamous cell carcinoma of the lung
    Chen, Zhiyong
    Yi, Li
    Peng, Zhiwei
    Zhou, Jianzhong
    Zhang, Zhaotao
    Tao, Yahong
    Lin, Ze
    He, Anjing
    Jin, Mengni
    Zuo, Minjing
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [37] Prediction of EGFR mutation status in lung adenocarcinoma based on 18F-FDG PET/CT radiomic features
    Tan, Jian-Ling
    Xia, Liang
    Sun, Su-Guang
    Zeng, Hui
    Lu, Di-Yu
    Cheng, Xiao-Jie
    AMERICAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 13 (05): : 230 - +
  • [38] Additional value of metabolic parameters to PET/CT-based radiomics nomogram in predicting lymphovascular invasion and outcome in lung adenocarcinoma
    Pei Nie
    Guangjie Yang
    Ning Wang
    Lei Yan
    Wenjie Miao
    Yanli Duan
    Yanli Wang
    Aidi Gong
    Yujun Zhao
    Jie Wu
    Chuantao Zhang
    Maolong Wang
    Jingjing Cui
    Mingming Yu
    Dacheng Li
    Yanqin Sun
    Yangyang Wang
    Zhenguang Wang
    European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48 : 217 - 230
  • [39] Value of multi-center 18F-FDG PET/CT radiomics in predicting EGFR mutation status in lung adenocarcinoma
    Zuo, Yan
    Liu, Liu
    Chang, Cheng
    Yan, Hui
    Wang, Lihua
    Sun, Dazhen
    Ruan, Maomei
    Lei, Bei
    Xia, Xunpeng
    Xie, Wenhui
    Song, Shaoli
    Huang, Gang
    MEDICAL PHYSICS, 2024, 51 (07) : 4872 - 4887
  • [40] The value of CT shape quantification in predicting pathological classification of lung adenocarcinoma
    Guo, Mingjie
    Cao, Zhan
    Huang, Zhichao
    Hu, Shaowen
    Xiao, Yafei
    Ding, Qianzhou
    Liu, Yalong
    An, Xiaokang
    Zheng, Xianjie
    Zhang, Shuanglin
    Zhang, Guoyu
    BMC CANCER, 2024, 24 (01)